Objective. Robotic liver surgery (RLS) has emerged as a feasible alternative to laparoscopic or open resections with comparable perioperative outcomes. Little is known about the oncologic adequacy of RLS. The purpose of this study was to investigate the long-term oncologic outcomes for patients undergoing RLS for primary hepatobiliary malignancies. Methods. We performed an international, multicenter, retrospective study of patients who underwent RLS for hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), or gallbladder cancer (GBC) between 2006 and 2016. Age, gender, histology, resection margin status, extent of surgical resection, disease-free survival (DFS), and overall survival (OS) were retrospectively collected and analyzed. Results. Of the 61 included patients, 34 (56%) had RLS performed for HCC, 16 (26%) for CC, and 11 (18%) for GBC. The majority of resections were nonanatomical or segmental resections (39.3%), followed by central hepatectomy (18%), left-lateral sectionectomy (14.8%), left hepatectomy (13.1%), right hepatectomy (13.1%), and right posterior segmentectomy (1.6%). R0 resection was achieved in 94% of HCC, 68% of CC, and 81.8% of GBC patients. Median hospital stay was 5 days, and conversion to open surgery was needed in seven patients (11.5%). Grade III-IV Dindo-Clavien complications occurred in seven patients with no perioperative mortality. Median follow-up was 75 months (95% confidence interval 36-113), and 5-year OS and DFS were 56 and 38%, respectively. When stratified by tumor type, 3-year OS was 90% for HCC, 65% for GBC, and 49% for CC (p = 0.01). Conclusions. RLS can be performed for primary hepatobiliary malignancies with long-term oncologic outcomes comparable to published open and laparoscopic data.
Primary hepatobiliary cancers (PHBC) are one of the most common cancers; hepatocellular carcinoma (HCC) ranks second in cancer-related deaths worldwide and sixth in cancer-related deaths in developed countries.
1,2 More than 20,000 new diagnoses of HCC are made yearly in the United States with an annual incidence of approximately 780,000 new cases worldwide. [2] [3] [4] Cholangiocarcinoma (CC) and gallbladder cancer (GBC) less common than HCC, share a similar poor prognosis. 1, 5 The surgical management of PHBC has evolved over recent decades with the advent of minimally invasive surgery. Since the introduction of laparoscopic liver surgery (LLS) in the 1990s, multiple studies have reported on its safety and feasibility. [6] [7] [8] [9] [10] [11] [12] [13] In 2008, the first international consensus meeting was held in Louisville, Kentucky, to establish indications for LLS. These criteria included utilization of laparoscopy for solitary lesions smaller than 5 cm, for lesions in segments 2 through 6, for left-lateral sectionectomies, and reserving right or left hepatectomies for surgeons highly experienced in laparoscopy.
14 Since 2008, laparoscopy gained significant popularity for liver resections and a second international consensus conference was held in Morioka, Japan, in 2014 with the goal of developing more specific guidelines. 15 They concluded that minor LLS is now standard practice, whereas major LLS is considered innovative, and robotic liver resections should be categorized as developmental. An increased interest in the utilization of robot techniques for hepatic resections emerged as the limitations associated with LLS, including its restricted visualization to two dimensions and limited range of motion to four degrees became more apparent. [17] [18] [19] The short-term outcomes following RLS have recently been studied; many reports demonstrated similar perioperative morbidity and mortality compared with LLS. 6, [19] [20] [21] [22] [23] [24] 31 Despite limited reports on the long-term oncologic outcomes following LLS demonstrating no differences in overall or disease-free survival compared with open liver resections (OLR), little is known regarding the actual oncologic efficacy of RLS. 16, [25] [26] [27] [28] [29] [30] This study examined the oncologic outcomes of RLS performed for PHBC with particular interest in overall survival (OS) and recurrence rates (RR).
METHODS

Patients and Indications
Patients with a diagnosis of HCC, CC, or GBC were discussed at multidisciplinary conferences at their respective institutions. Diagnoses were based on clinical presentation, elevated serum tumor markers (alpha fetoprotein for HCC and CA19.9 for CC and GBC), and crosssectional imaging. Surgical resectability was based on patient's ability to undergo general anesthesia and pneumoperitoneum while following general consensus guidelines for LLS as surrogate.
14,32 RLS was performed with the intention to cure and diagnoses were confirmed by institutional surgical pathology.
Operative Technique
All patients underwent surgery with the assistance of the da Vinci Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) robotic-assisted platform. Details on the setup, use, and technical considerations of the robotic system were similar to that found in published literature. 22, [32] [33] [34] Intraoperative ultrasound was performed to guide resection. Ligasure, harmonic scalpel, and endovascular GIA staplers were used during parenchymal transections and control of vasculature. If safe or successful resection was not attainable, the operation was converted to open. 
Data Collection
Statistical Analysis
The database was analyzed using SPSS v24 software. Continuous variables were expressed as means and medians and were compared using the Student t test if normally distributed or Wilcoxon-Mann-Whitney test for nonparametric variables. Discrete variables were expressed as frequency and percentages and Chi square or Fisher exact test, when appropriate, were used for comparisons. Kaplan-Meier curves were used to calculate the probability of survival and comparisons were performed using logrank test. Patients who were alive and patients who did not have recurrent disease at the time of the last follow-up were censored. Two-tail tests were used for all comparison, and p values B 0.05 were considered statistically significant. Complications were classified based on the Dindo-Clavien grading system. 35 
RESULTS
Demographics and Perioperative Outcomes
Between September 2006 and November 2016, 61 patients underwent RLS for PHBC. Thirty-four (56%) of the 61 patients were diagnosed with HCC, 16 (26%) with CC, and 11 (18%) with GBC. The median age was 66 (range 32-91) years; females comprised 41% of the overall cohort. Cirrhosis was present in 22.8% (n = 14) of patients, of which 12 had Childs-Pugh class A cirrhosis, 2 had class B, and none had class C cirrhosis. Four (6.5%) patients underwent prior liver resections, including two right hepatectomies for HCC, one emergent partial right lobectomy for a ruptured HCC, and one unspecified liver resection (Table 1) .
There were no perioperative mortalities. Approximately one-third of patients (34.4%, n = 23) experienced perioperative complications, with 11.5% (n = 7) classified as Dindo-Clavien Grade 3 or greater. 30 Complications of respiratory function were the most common (n = 11), including atelectasis/pulmonary edema (n = 3), respiratory insufficiency (n = 2), respiratory failure (n = 2), pneumonia (n = 2), and PE (n = 2). One patient with HCC and alcoholic cirrhosis developed liver failure, ultimately requiring liver transplantation. The median LOS was 5 (range 2-91) days (Table 2) .
Operative Outcomes
The majority of patients underwent a nonanatomical liver resection or segmentectomy (n = 24, 39.3%), followed by left-lateral sectionectomy (n = 9, 14.8%) left hepatectomy (n = 8, 13.1%), right hepatectomy (n = 8, 13.1%), and one patient underwent right posterior segmentectomy. Eighteen percent (n = 11) of patients underwent central liver resection, all of which were for GBC.
Median operative time was 240 (range 99-790) minutes, and EBL was 100 (range 2-2200) cc (Table 2 ). Seven cases (11.5%) required conversion to open. Of the patients who were converted to open, three underwent a nonanatomical liver resections, three underwent a right hepatectomy, and one underwent a left hepatectomy. Reasons for conversion included uncontrolled bleeding (n = 1), advanced disease (n = 2), inadequate margins (n = 2), adhesions (n = 1), and technical difficulty (n = 1). Of the seven patients who underwent conversion to open, three had multifocal HCC with tumor sizes ranging from 5.0 to 14.5 cm, and four had CC of which three were Klatskin tumors. All patients who underwent conversion to open had an EBL higher than the median (range 500-1200 cc) and LOS longer than our median (range 8-91 days). Patients with CC had higher likelihood of conversion to open (n = 4, 25%) compared with patients with HCC (n = 3, 8.8%) and GBC (n = 0, 0%). Seventyfive percent (n = 3) of these were Klatskin tumors. One was Bismuth stage 1, and two were Bismuth stage 2. 36 All 
Pathologic Characteristics
The majority of patients (49.2%, n = 30) had moderately differentiated tumors. Median tumor size was 3.4 (range 0.3-16) cm. R0 resection was achieved in 85.2%; a subanalysis showed R0 resection in 94.1% in patients with HCC, 81.8% in GBC, and 68.8% in CC (Table 3) . Patients with HCC most commonly had tumor burden within one segment (n = 13, 38.2%), whereas the majority of patients with CC and GBC had tumor burden within two segments (n = 6, 37.5%; n = 11, 100%, respectively). The average number of lymph nodes resected for HCC was 2 (range 0-6), GBC 5 (range 0-9), and CC 2.5 (0-13).
Oncologic Outcomes
Median follow-up for patients was 75 months (95% confidence interval [CI] 26-113 months), with RR of 37.7% (n = 23). For patients who were diagnosed with HCC, 44% (n = 15) developed recurrence of which the majority (n = 10) recurred in the liver. Patients with CC had RR of 31.2% (n = 5); the most common site also was the liver (n = 3). Recurrence was lowest in patients with GBC (27.2%; n = 3); all three patients had evidence of malignancy in multiple organs. No port site recurrences were found. For the entire cohort, systemic chemotherapy (n = 9) and liver-directed therapy (n = 6) were the most common methods of management of the recurrence disease. At 5 years, the overall survival (OS) and disease-free survival (DFS) for the entire cohort were 56 and 38% respectively (Fig. 1) . Subgroup analysis showed a 3-year survival of 90% for HCC, 65% for GBC, and 49% for CC (Fig. 2) .
DISCUSSION
The results of this multicenter study suggest that RLS performed for PHBC demonstrate similar long-term oncologic adequacy compared with laparoscopic or open techniques. A review of more than 2800 patients who underwent LLS for HCC found a 5-year OS rate between 50 and 75% and a DFS rate ranging from 31 to 38.2%. 7 Our cohort had similar outcomes with an OS of 56% and DFS of 38%. Lai et al. studied 41 patients who underwent RLS for HCC reporting an R0 rate of 93% and OS rate of 94%, comparable to the R0 rate of 94% and 3 year OS of 90% observed with HCC in the current study. 37 Takahara et al. reported a 5-year OS/DFS rate of 70.9%/39.3% in patients undergoing OLR. 25 Subgroup analyses of patients with HCC in our study showed comparable OS and DFS. One study by Wu et al. reviewed a larger cohort of patients (n = 38) with HCC and discusses their ability to increase the number of patients undergoing MIS with the addition of RLS. However, this study does not examine any long-term oncologic outcomes. 38 The only current data on RLS for CC consists of one study that compared 10 robotic radical resections to 32 OLR for hilar cholangiocarcinoma. This study concluded an inferior DFS and OS rate associated with RLS. 33 It is difficult to compare these patients to our cohort, because only 3 of the 16 patients within our cohort underwent RLS for hilar-type CC. Our data showed a median survival time of 17 months, 100% conversion rate, higher EBL, and longer LOS. The data from our study, along with the limited historical data on RLS for CC, suggest inferiority in outcomes for patients undergoing RLS for extrahepatic CC. Uy et al. evaluated 37 patients with intrahepatic cholangiocarcinoma (IHC). They reported 5-year OS and DFS rates for the laparoscopic cohort of 77.9 and 56.2%, respectively. 31 Although these rates seem higher than the 5-year OS/DFS rate of 56%/38% and the 3-year CC specific OS rate of 49% that we observed, their cohort comprised of intrahepatic CC only and their median follow-up was limited to 17.
For patients with GBC, the only study to report RLS compared 5 patients who underwent a robotic radical cholecystectomy to 18 patients who underwent OLR. Their maximum follow-up was 17 months, and only one patient underwent a lymphadenectomy. 39 Recently, an expert consensus statement on laparoscopic resection of GBC showed that this approach did not worsen the prognosis and allowed comparable retrieval of lymph nodes to open surgery in experienced centers. 40 Palanisamy et al. studied 14 patients with GBC who underwent LLS and reported an R0 resection rate of 100% and 5-year OS of 68.8%. 41 Although the R0 resection rate observed in our study for GBC (R0 = 81.8%) is lower, we showed comparable longterm survival outcomes with a 3-year OS rate of 65%.
Despite this study reporting comparable oncologic outcomes to LLS, the median operative time associated with RLS (240 min), as seen in prior published studies, is longer. 21, 33, 42, 43 When stratified by type of liver resection, our data show the longest operative times are associated with right lobectomies and the shortest operative times with left-lateral sectionectomies. The longest operative time, 790 min, was seen at an institution that performed less than five RLS cases over the 10-year period, emphasizing variation in outcome depending on experience of institution. The heterogeneity of pathology also plays a factor; resections for hilar cholangiocarcinoma also were associated with longer operative times, similar to published studies. 31 Despite this, we believe that a minimally invasive approach can still offer benefits, including shorter LOS, decreased EBL, and postoperative complications compared with OLR.
11,44
The major limitation to this study is that although it is one of the largest series to date of RLS for PHBC, 61 patients over a 10-year period emphasized how infrequently RLS is performed for PHBC. Our data do show a trend of increase in utilization of the robot with time as the number of RLS performed from 2006 to 2011 ranged from 1 to 4 per year, which then increased to 4-13 per year starting in 2012. It also shows that some institutions started performing RLS but never continued, exhibiting that support and access of this technology is not the same throughout all institutions performing liver surgery. We included robotic cases from a 10-year period, because it allows us not only to track patients' oncologic outcomes over an extended period but also provides real-world experience of the perioperative outcomes from both lowand high-volume centers.
This retrospective study by nature of its design allows for selection bias, because each individual surgeon was able to decide on the candidacy for robotic surgery. The lower number of cirrhotic patients with HCC (32%) in this study compared with the published literature (56-100%) was likely due to the fact that surgeons chose to perform RLS in overall healthier patients without cirrhosis, who would likely better tolerate longer anesthesia time. 45 Cipriani et al. performed a matched comparison between cirrhotic patients and noncirrhotic patients, reporting that the former exhibited a higher incidence of recurrence and supporting that the lower RR reported in this study also could be due to the smaller percentage of patients with cirrhosis. 46 The current study has several strengths, including the relatively large number of participants who were operated on in the United States and Europe in a variety of institutions that ranged from very low-volume centers to highervolume centers, allowing us to study the wide variety of the outcomes.
CONCLUSIONS
This international, multicenter study examined the longterm oncologic outcomes of patients undergoing RLS for PHBC and demonstrated them to be noninferior to the published data on laparoscopic or open liver resections for PHBC. As RLS has become an increasingly utilized alternative to laparoscopic or open surgery, future efforts in prospective observational or randomized, controlled trials must be designed to assess the overall benefits and possible limitations of robotic-assisted surgery for liver resections for hepatobiliary malignancies.
